Scientific Reports (Feb 2022)

Prognostic value of postural hypotension in hospitalized patients with heart failure

  • Tsutomu Sunayama,
  • Daichi Maeda,
  • Yuya Matsue,
  • Nobuyuki Kagiyama,
  • Kentaro Jujo,
  • Kazuya Saito,
  • Kentaro Kamiya,
  • Hiroshi Saito,
  • Yuki Ogasawara,
  • Emi Maekawa,
  • Masaaki Konishi,
  • Takeshi Kitai,
  • Kentaro Iwata,
  • Hiroshi Wada,
  • Masaru Hiki,
  • Taishi Dotare,
  • Takatoshi Kasai,
  • Hirofumi Nagamatsu,
  • Tetsuya Ozawa,
  • Katsuya Izawa,
  • Shuhei Yamamoto,
  • Naoki Aizawa,
  • Ryusuke Yonezawa,
  • Kazuhiro Oka,
  • Shin-ichi Momomura,
  • Tohru Minamino

DOI
https://doi.org/10.1038/s41598-022-06760-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Although postural hypotension (PH) is reportedly associated with mortality in the general population, the prognostic value for heart failure is unclear. This was a post-hoc analysis of FRAGILE-HF, a prospective multicenter observational study focusing on frailty in elderly patients with heart failure. Overall, 730 patients aged ≥ 65 years who were hospitalized with heart failure were enrolled. PH was defined by evaluating seated PH, and was defined as a fall of ≥ 20 mmHg in systolic and/or ≥ 10 mmHg in diastolic blood pressure within 3 min after transition from a supine to sitting position. The study endpoints were all-cause death and heart failure readmission at 1 year. Predictive variables for the presence of PH were also evaluated. PH was observed in 160 patients (21.9%). Patients with PH were more likely than those without PH to be male with a New York Heart Association classification of III/IV. Logistic regression analysis showed that male sex, severe heart failure symptoms, and lack of administration of angiotensin-converting enzyme inhibitors were independently associated with PH. PH was not associated with 1-year mortality, but was associated with a lower incidence of readmission after discharge after adjustment for other covariates. In conclusion, PH was associated with reduced risk of heart failure readmission but not with 1-year mortality in older patients with heart failure.